MCM
ARQT icon

MAI Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

MAI Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-152
Closed -$3.58K – 2258
2026
Q1 		$3.58K Buy
152
+136
+850% +$3.47K ﹤0.01% 3678
2025
Q4 		$465 Buy
+16
New +$410 ﹤0.01% 3844

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

MAI Capital Management's ARQT Position: Q2 2026 in Review

MAI Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 152 shares — an estimated $3.58K sold.

MAI Capital Management first reported a position in ARQT in Q4 2025 and held it in 2 quarters. The position peaked at $3.58K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • MAI Capital Management reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 152 Arcutis Biotherapeutics shares in Q2 2026, an estimated $3.58K.
  • MAI Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Arcutis Biotherapeutics position peaked at $3.58K in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.